Rakuten Medical Announces Recent Interim Data from Phase 1b/2 Clinical Trial of ASP-1929 Photoimmunotherapy in ...
Overall survival rate estimated at 24 months was 52.4% with generally tolerated safety profile Completed a Type B End-of-Phase 2 (EOP2) meeting with the US FDA for the combination (ASP-1929 photoimmunotherapy and anti-PD-1) in the first-line recurrent …